OWA
CRSP icon

Opal Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Opal Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.4K Buy
+681
New +$35.9K 0.01% 480
2024
Q3 		– Sell
-200
Closed -$10.8K – 406
2024
Q2 		$10.8K Buy
+200
New +$11.6K ﹤0.01% 643

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opal Wealth Advisors's CRSP Position: Q1 2026 in Review

Opal Wealth Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 681 shares worth $32.4K. The stake represents 0.01% of the portfolio and ranks #480 among its holdings. This is a return to the name: Opal Wealth Advisors previously reported a position in CRSP as recently as Q2 2024.

Opal Wealth Advisors first reported a position in CRSP in Q2 2024 and has held it in 2 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Opal Wealth Advisors held 681 shares of CRISPR Therapeutics worth $32.4K as of Q1 2026.
  • CRISPR Therapeutics was a new Opal Wealth Advisors position in Q1 2026.
  • CRISPR Therapeutics made up 0.01% of Opal Wealth Advisors's portfolio in Q1 2026, its #480 holding.
  • Opal Wealth Advisors first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Opal Wealth Advisors's 13F filing for Q1 2026, filed 14 Apr 2026.